Safety and efficacy of neoadjuvant pembrolizumab in mismatch repair deficient localized/locally advanced solid tumors.

被引：7
|
作者：
Ludford, Kaysia
Raghav, Kanwal Pratap Singh
Murphy, Mariela A. Blum
Fleming, Nicole D.
Nelson, Douglas A.
Lee, Michael Sangmin
Smaglo, Brandon George
You, Y. Nancy
Tillman, Matthew Murray
Kamiya-Matsuoka, Carlos
Thirumurthi, Selvi
Messick, Craig
Johnson, Benny
Sanchez, Eduardo Vilar
Dasari, Arvind
Thomas, Jane V.
Foo, Wai Chin
Qiao, Wei
Kopetz, Scott
Overman, Michael J.
机构：
[1] Univ Texas MD Anderson, Houston, TX USA
[2] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[3] Univ Texas MD Anderson Canc Ctr, The Woodlands, TX USA
[4] Univ Texas MD Anderson Canc Ctr, Dept Colon & Rectal Surg, Houston, TX 77030 USA
[5] Univ Texas MD Anderson Canc Ctr, Dept Neurooncol, Houston, TX 77030 USA
[6] Univ Texas MD Anderson Canc Ctr, Dept Gastroenterol, Houston, TX 77030 USA
[7] Univ Texas MD Anderson Canc Ctr, Dept Surg Oncol, Houston, TX 77030 USA
[8] Univ Texas MD Anderson Canc Ctr, Dept Gastrointestinal Med Oncol, Houston, TX 77030 USA
[9] Univ Texas MD Anderson Canc Ctr, Dept Clin Canc Prevent, Houston, TX 77030 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2021年 / 39卷 / 15期
关键词：
D O I：
10.1200/JCO.2021.39.15_suppl.2520
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2520
引用
下载
收藏
页数：2
相关论文
共 50 条
  • [1] Neoadjuvant pembrolizumab in localized/locally advanced solid tumors with mismatch repair deficiency
    Ludford, K.
    Raghav, K.
    Murphy, M. A. Blum
    Fleming, N. D.
    Nelson, D.
    Lee, M. S.
    Smaglo, B. G.
    You, Y. N.
    Tillman, M. M.
    Kamiya-Matsuoka, C.
    Thirumurthi, S.
    Messick, C.
    Johnson, B.
    Vilar, E.
    Thomas, J.
    Foo, W. C.
    Qiao, W.
    Kopetz, S.
    Overman, M. J.
    ANNALS OF ONCOLOGY, 2021, 32 : S1210 - S1210
  • [2] Neoadjuvant Pembrolizumab in Localized Microsatellite Instability High/Deficient Mismatch Repair Solid Tumors
    Ludford, Kaysia
    Ho, Won Jin
    Thomas, Jane V.
    Raghav, Kanwal P. S.
    Murphy, Mariela Blum
    Fleming, Nicole D.
    Lee, Michael S.
    Smaglo, Brandon G.
    You, Y. Nancy
    Tillman, Matthew M.
    Kamiya-Matsuoka, Carlos
    Thirumurthi, Selvi
    Messick, Craig
    Johnson, Benny
    Vilar, Eduardo
    Dasari, Arvind
    Shin, Sarah
    Hernandez, Alexei
    Yuan, Xuan
    Yang, Hongqui
    Foo, Wai Chin
    Qiao, Wei
    Maru, Dipen
    Kopetz, Scott
    Overman, Michael J.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (12) : 2181 - +
  • [3] Neoadjuvant Immunotherapy in Locally Advanced Mismatch Repair-Deficient Colon Cancer
    Chalabi, Myriam
    Verschoor, Yara L.
    Tan, Pedro Batista
    Balduzzi, Sara
    Van Lent, Anja U.
    Grootscholten, Cecile
    Dokter, Simone
    Bueller, Nike V.
    Grotenhuis, Brechtje A.
    Kuhlmann, Koert
    Burger, Jacobus W.
    Huibregtse, Inge L.
    Aukema, Tjeerd S.
    Hendriks, Eduard R.
    Oosterling, Steven J.
    Snaebjornsson, Petur
    Voest, Emile E.
    Wessels, Lodewyk F.
    Beets-Tan, Regina G.
    Van Leerdam, Monique E.
    Schumacher, Ton N.
    van den Berg, Jose G.
    Beets, Geerard L.
    Haanen, John B.
    NEW ENGLAND JOURNAL OF MEDICINE, 2024, 390 (21): : 1949 - 1958
  • [4] Efficacy and safety of neoadjuvant immune checkpoint inhibitors in patients with localized mismatch repair deficient colorectal cancer: A systematic review.
    Grewal, Udhayvir Singh
    Vora, Kruti Bhagirath
    Parikh, Aparna Raj
    Mahipal, Amit
    Chakrabarti, Sakti
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 : 149 - 149
  • [5] A phase 2 study of tislelizumab monotherapy in patients with previously treated, locally advanced unresectable ormetastatic microsatellite instability-high/mismatch repair deficient solid tumors.
    Li, Jian
    Xu, Ye
    Zang, Aimin
    Gao, Yunong
    Gao, Quanli
    Zhang, Yanqiao
    Wang, Dong
    Xu, Jianming
    Yuan, Ying
    Jiang, Haiping
    Ying, Jieer
    Shi, Chunmei
    Deng, Yanhong
    Wang, Jing
    Liu, Tianshu
    Huang, Yi
    Li, Zhezhen
    Wang, Huanli
    Liu, Shou
    Shen, Lin
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [6] Systematic Review of Neoadjuvant Immunotherapy for Mismatch Repair Deficient Locally Advanced Colon Cancer: An Emerging Strategy
    Loria, Anthony
    Ammann, Allison
    Olowokure, Olugbenga
    Paquette, Ian
    Justiniano, Carla
    DISEASES OF THE COLON & RECTUM, 2024, 67 (06) : 762 - 771
  • [7] Pembrolizumab in patients of Chinese descent with microsatellite instability-high/mismatch repair deficient advanced solid tumors: KEYNOTE-158
    Wu, X.
    Mao, Y.
    Xu, N.
    Bai, Y.
    Wang, D.
    Chen, X.
    Yin, X.
    Deng, Y.
    Yang, J.
    Zhang, J.
    Tang, J.
    Huang, Y.
    Li, J.
    Xu, M.
    Li, N.
    Mao, Y.
    Gozman, A.
    Xu, J.
    ANNALS OF ONCOLOGY, 2023, 34 : S1707 - S1707
  • [8] Pembrolizumab in patients of Chinese descent with microsatellite instability-high/mismatch repair deficient advanced solid tumors: KEYNOTE-158
    Mao, Y.
    Wu, X.
    Xu, N.
    Bai, Y.
    Wang, D.
    Chen, X.
    Yin, X.
    Deng, Y.
    Yang, J.
    Zhang, J.
    Tang, J.
    Huang, Y.
    Li, J.
    Xu, M.
    Li, N.
    Mao, Y.
    Gozman, A.
    Xu, J.
    ANNALS OF ONCOLOGY, 2023, 34 : S235 - S235
  • [9] An open label phase I study to evaluate the safety and efficacy of OBP-301 with pembrolizumab in patients with advanced solid tumors.
    Kojima, Takashi
    Fujiwara, Toshiyoshi
    Shirakawa, Yasuhiro
    Ono, Hiromi
    Nakamoto, Masako
    Hasegawa, Hiromi
    Hirano, Nami
    Wakabayashi, Masashi
    Nomura, Shogo
    Togashi, Yosuke
    Nishikawa, Hiroyoshi
    Sato, Akihiro
    Ohtsu, Atsushi
    Doi, Toshihiko
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [10] Neoadjuvant pembrolizumab for localized solid MSI-H/dMMR tumors
    Kessing, Richard
    ZEITSCHRIFT FUR GASTROENTEROLOGIE, 2023, 61 (10):
12345